Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives

Chunhua Yang,1 Didier Merlin1,2 1Institute for Biomedical Sciences, Center for Diagnostics and Therapeutics, Digestive Disease Research Group, Georgia State University, Atlanta, GA 30302, USA; 2Atlanta Veterans Affairs Medical Center, Decatur, GA 30033, USACorrespondence: Chunhua YangInstitute for B...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yang C, Merlin D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	intestinal bowel disease nanoparticle multi-responsive edible-plant derived exosome targeted drug delivery Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/95dc47a1a78b441ea911f14b7f6894be
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:95dc47a1a78b441ea911f14b7f6894be
record_format	dspace
spelling	oai:doaj.org-article:95dc47a1a78b441ea911f14b7f6894be2021-12-02T06:56:20ZNanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives1178-2013https://doaj.org/article/95dc47a1a78b441ea911f14b7f6894be2019-11-01T00:00:00Zhttps://www.dovepress.com/nanoparticle-mediated-drug-delivery-systems-for-the-treatment-of-ibd-c-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Chunhua Yang,1 Didier Merlin1,2 1Institute for Biomedical Sciences, Center for Diagnostics and Therapeutics, Digestive Disease Research Group, Georgia State University, Atlanta, GA 30302, USA; 2Atlanta Veterans Affairs Medical Center, Decatur, GA 30033, USACorrespondence: Chunhua YangInstitute for Biomedical Sciences, Center for Diagnostics and Therapeutics, Digestive Disease Research Group, Georgia State University, Piedmont Ave SE, Atlanta, GA 30302, USATel +1 404 413 3597Fax +1 404 413 3580Email cyang16@gsu.eduAbstract: Inflammatory bowel disease (IBD), which mainly consists of Crohn’s disease and ulcerative colitis, is a chronic and relapsing inflammatory condition of the gastrointestinal tract. The traditional treatment strategies relied on frequent administration of high dosages of medications, including antibiotics, non-steroidal anti-inflammatory drugs, biologics, and immunomodulators, with the goal of reducing inflammation. Some of these medications were effective in alleviating the early-stage inflammatory symptoms, but their long-term efficacies were compromised by the accumulation of toxicities. Recently, nanoparticle (NP)-based drugs have been widely studied for their potential to solve such problems. Various mechanisms/strategies, including size-, charge-, pH-, pressure-, degradation-, ligand-receptor-, and microbiome- dependent drug delivery systems, have been exploited in preclinical studies. A certain number of NP delivery systems have sought to target drugs to the inflamed intestine. Although several NP-based drugs have entered clinical trials for the treatment of IBD, most have failed due to premature drug release, weak targeting ability, and the high immune toxicity of some of the synthetic nanomaterials that have been used to fabricate the NPs. Therefore, there is still a need for rationally designed and stable NP drug delivery system that can specifically target drugs to the disease site, prolong the drug’s residence time, and minimize systemic side effects. This review will analyze the current state of the art in NP-mediated drug delivery for IBD treatment. We will focus on topics such as deliverable targets (at the tissue or cellular level) for treating inflammation; the target-homing NP materials that can interact with such targets; and the major administration routes for treating IBD. These discussions will integrate notable trends in the research and development of IBD medications, including multi-responsive NP-mediated delivery and naturally-derived targeting NPs. Finally, current challenges and future directions will be presented in the hopes of advancing the study of NP-mediated strategies for treating IBD.Keywords: intestinal bowel disease, nanoparticle, multi-responsive, edible-plant derived, exosome, targeted drug deliveryYang CMerlin DDove Medical Pressarticleintestinal bowel diseasenanoparticlemulti-responsiveedible-plant derivedexosometargeted drug deliveryMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 8875-8889 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	intestinal bowel disease nanoparticle multi-responsive edible-plant derived exosome targeted drug delivery Medicine (General) R5-920
spellingShingle	intestinal bowel disease nanoparticle multi-responsive edible-plant derived exosome targeted drug delivery Medicine (General) R5-920 Yang C Merlin D Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives
description	Chunhua Yang,1 Didier Merlin1,2 1Institute for Biomedical Sciences, Center for Diagnostics and Therapeutics, Digestive Disease Research Group, Georgia State University, Atlanta, GA 30302, USA; 2Atlanta Veterans Affairs Medical Center, Decatur, GA 30033, USACorrespondence: Chunhua YangInstitute for Biomedical Sciences, Center for Diagnostics and Therapeutics, Digestive Disease Research Group, Georgia State University, Piedmont Ave SE, Atlanta, GA 30302, USATel +1 404 413 3597Fax +1 404 413 3580Email cyang16@gsu.eduAbstract: Inflammatory bowel disease (IBD), which mainly consists of Crohn’s disease and ulcerative colitis, is a chronic and relapsing inflammatory condition of the gastrointestinal tract. The traditional treatment strategies relied on frequent administration of high dosages of medications, including antibiotics, non-steroidal anti-inflammatory drugs, biologics, and immunomodulators, with the goal of reducing inflammation. Some of these medications were effective in alleviating the early-stage inflammatory symptoms, but their long-term efficacies were compromised by the accumulation of toxicities. Recently, nanoparticle (NP)-based drugs have been widely studied for their potential to solve such problems. Various mechanisms/strategies, including size-, charge-, pH-, pressure-, degradation-, ligand-receptor-, and microbiome- dependent drug delivery systems, have been exploited in preclinical studies. A certain number of NP delivery systems have sought to target drugs to the inflamed intestine. Although several NP-based drugs have entered clinical trials for the treatment of IBD, most have failed due to premature drug release, weak targeting ability, and the high immune toxicity of some of the synthetic nanomaterials that have been used to fabricate the NPs. Therefore, there is still a need for rationally designed and stable NP drug delivery system that can specifically target drugs to the disease site, prolong the drug’s residence time, and minimize systemic side effects. This review will analyze the current state of the art in NP-mediated drug delivery for IBD treatment. We will focus on topics such as deliverable targets (at the tissue or cellular level) for treating inflammation; the target-homing NP materials that can interact with such targets; and the major administration routes for treating IBD. These discussions will integrate notable trends in the research and development of IBD medications, including multi-responsive NP-mediated delivery and naturally-derived targeting NPs. Finally, current challenges and future directions will be presented in the hopes of advancing the study of NP-mediated strategies for treating IBD.Keywords: intestinal bowel disease, nanoparticle, multi-responsive, edible-plant derived, exosome, targeted drug delivery
format	article
author	Yang C Merlin D
author_facet	Yang C Merlin D
author_sort	Yang C
title	Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives
title_short	Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives
title_full	Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives
title_fullStr	Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives
title_full_unstemmed	Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives
title_sort	nanoparticle-mediated drug delivery systems for the treatment of ibd: current perspectives
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/95dc47a1a78b441ea911f14b7f6894be
work_keys_str_mv	AT yangc nanoparticlemediateddrugdeliverysystemsforthetreatmentofibdcurrentperspectives AT merlind nanoparticlemediateddrugdeliverysystemsforthetreatmentofibdcurrentperspectives
_version_	1718399706864812032

Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives

Ejemplares similares